Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients

被引：0

作者：

Singh, Dave ^{[1
]}

Govoni, Mirco ^{[2
]}

Bassi, Michele ^{[2
]}

Beeh, Kai Michael ^{[3
]}

Colgan, Brendan ^{[4
]}

Kornmann, Oliver ^{[5
]}

Laeker, Brian ^{[6
]}

Watz, Henrik ^{[7
]}

Lucci, Germano ^{[2
]}

Geraci, Silvia ^{[2
]}

Rocco, Emanuele Calabro ^{[2
]}

Emirova, Aida ^{[8
]}

Nandeuil, Marie Anna ^{[8
]}

机构：

[1] Univ Manchester, Med Evaluat Unit, Manchester, Lancs, England

[2] Chiesi Farmaceut SpA, Global Clin Dev, Parma, Italy

[3] Insaf Resp Res Inst, Wesbaden, Germany

[4] Celerion, Belfast, Antrim, North Ireland

[5] IKF Pneumol Frankfurt, Clin Res Ctr Resp Dis, Frankfurt, Germany

[6] Heart Lung Ctr, London, England

[7] Lung Clin, Pulm Res Inst, Grosshansdorf, Germany

[8] Chiesi SAS, Global Clin Dev, Bois Colombes, France

来源：

EUROPEAN RESPIRATORY JOURNAL | 2019年 / 54卷

关键词：

Biomarkers; COPD; -; management; Anti-inflammatory;

D O I：

10.1183/13993003.congress-2019.PA2044

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

PA2044

引用

页数：2

共 50 条

[31] Anti-inflammatory effects of the phosphodiesterase type 4 inhibitor CHF6001 on bronchoalveolar lavage lymphocytes from asthma patients
Southworth, Thomas
Kaur, Manminder
Hodgson, Lynsey
Facchinetti, Fabrizio
Villetti, Gino
Civelli, Maurizio
Singh, Dave
CYTOKINE, 2019, 113 : 68 - 73
[32] Synthesis of 14C- and 2H-labelled CHF6001: A new potent PDE4 inhibitor
Fontana, E.
Cenacchi, V.
Pivetti, F.
Pignatti, A.
Pazzi, T.
Bondanza, L.
Pazzi, M.
JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 (12): : 577 - 585
[33] Evaluation of oral corticosteroids and phosphodiesterase-4 inhibitor on the acute inflammation induced by inhaled lipopolysaccharide in human☆
Michel, Olivier
Dentener, Mieke
Cataldo, Didier
Cantinieaux, Brigitte
Vertongen, Francoise
Delvaux, Catherine
Murdoch, Robert D.
PULMONARY PHARMACOLOGY & THERAPEUTICS, 2007, 20 (06) : 676 - 683
[34] Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients
Porpodis, Konstantinos
Domvri, Kalliopi
Zarogoulidis, Paul
Petridis, Dimitrios
Tsirgogianni, Katerina
Papaioannou, Antonis
Hatzizisi, Olga
Kioumis, Ioannis
Liaka, Alexandra
Kikidaki, Violeta
Lampaki, Sofia
Organtzis, John
Zarogoulidis, Konstantinos
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 10 : 1123 - 1128
[35] Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)
Cameron, Ryan T.
Coleman, Ryan G.
Day, Jon P.
Yalla, Krishna C.
Houslay, Miles D.
Adams, David R.
Shoichet, Brian K.
Baillie, George S.
BIOCHEMICAL PHARMACOLOGY, 2013, 85 (09) : 1297 - 1305
[36] Effectiveness of roflumilast, a phosphodiesterase type-4 (PDE4) inhibitor on biomarkers of inflammation in COPD
Savelikhina, Iryna
Ostrovskyy, Mykola
Zuban, Alla
Varunkiv, Oleksandr
Kulynych-Miskiv, Mariana
Shvets, Kostiantyn
Korzh, Galyna
Makoyda, Iryna
Korzh, Nadiia
Shevchuk-Budz, Uliana
EUROPEAN RESPIRATORY JOURNAL, 2023, 62
[37] Efficacy and anti-inflammation activity of a selective phosphodiesterase-4 inhibitor cilomilast in treatment of COPD
Wang, CZ
Song, YX
Liao, XQ
Li, Q
Wang, JP
Zhao, ZQ
CHEST, 2005, 128 (04) : 262S - 262S
[38] The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia
Barreiro, Esther
Puig-Vilanova, Ester
Salazar-Degracia, Anna
Pascual-Guardia, Sergi
Casadevall, Carme
Gea, Joaquim
JOURNAL OF APPLIED PHYSIOLOGY, 2018, 125 (02) : 287 - 303
[39] Reduction in systemic inflammation by the PDE4 inhibitor roflumilast in patients with COPD
-Martin, Eduardo Marquez
Ruiz, Francisco Ortega
Campano, Elena
De la Horra, Carmen
Varela, Jose Manuel
Calderon, Enrique
EUROPEAN RESPIRATORY JOURNAL, 2014, 44
[40] Reduction in Systemic Inflammation by the PDE4 Inhibitor Roflumilast in Patients With COPD
Marquez-martin, Eduardo
Ortega, Francisco
Campano, Elena
de la Horra, Carmen
Varela, Jose
Calderon, Enrique
CHEST, 2013, 144 (04)

← 1 2 3 4 5 →